Effects of physical activity on cognitive performance: a controlled clinical study in depressive patients.

Physical activity is a common adjunctive therapy in psychiatric and psychosomatic hospitals. In the present study, we assessed the effects of an exercise program, integrated into routine inpatient treatment, on cognitive performance and subjective severity of depression in a sample of patients suffering from major depression. We randomized n = 38 patients with unipolar depression to either physical exercise (n = 18) or occupational therapy as an active control treatment (n = 20). Both treatments were delivered in group format over a period of 3-4 weeks. Data indicate that there were significant improvements of cognitive functions and depressive symptoms in both groups, with specific treatment effects in reaction time and in short-term verbal memory favoring the physical activity group. In conclusion, we found physical exercise to be a feasible, easy-to-implement add-on therapy for depressive patients with promising effects on cognitive performance. However, these results need to be replicated in larger samples with an extended follow-up.

[Neuropsychological treatment of cognitive deficits in substance abuse disorders, affective disorders, anxiety disorders and obsessive-compulsive disorders - current status and perspectives]. / Neuropsychologische Behandlung kognitiver Defizite bei Suchtmittel-, affektiven, Angst- und Zwangserkrankungen - Aktueller Stand und Perspektiven.

Neuropsychological treatment represents a promising therapeutic approach in the amelioration of cognitive deficits in many neuropsychiatric disorders. Cognitive impairment constitutes a core feature that often persists beyond psychopathological symptoms having a significant impact on psychosocial functioning. However, research interest and evidence of efficacy vary considerably between disease groups. Although neuropsychological treatment is frequently used in clinical practice, there are, with the exception of schizophrenia, relatively few studies on its effectiveness.

Driving performance and psychomotor function in depressed patients treated with agomelatine or venlafaxine.

OBJECTIVE: We conducted a randomized case-control study in depressive inpatients to assess the effects of agomelatine and venlafaxine on psychomotor functions related to driving skills and on driving performance in an on-road driving test. METHOD: 40 depressed inpatients treated with agomelatine (n = 20) or venlafaxine (n = 20) were tested before pharmacological treatment (t0), and on days 14 (t1) and 28 (t2). 20 healthy subjects were examined in the same time schedule to control for retest effects in psychomotor measures. Additionally, participants were rated in a standardized on-road driving test on day 28 by a licensed driving instructor, who was blind with respect to treatment, diagnosis and test results. RESULTS: After 4 weeks of treatment (t2) with agomelatine or venlafaxine, patients showed a significant reduction in depressive symptoms, and a distinct improvement in psychomotor functions. Controlling for retest effects in psychomotor measures, data indicate, that both patient groups significantly improved in tests measuring reactivity and stress-tolerance. Furthermore, prior discharge to outpatient treatment (day 28), 72.5% of patients were labeled abundantly fit to drive in the on-road driving test by a licensed driving instructor. However, patients did not reach the performance level of healthy controls in functional domains tested. Significant differences between treatment groups were not observed. CONCLUSION: Our results indicate that depressed inpatients treated with agomelatine or venlafaxine show a better test performance on tasks related to driving skills than do untreated depressives and could predominantly be rated as fit to drive on an actual driving test prior discharge to outpatient treatment.

[Dementia and driving]. / Demenz und Autofahren.

For most people driving is essential for mobility to maintain independence and to take part in activities of daily living. Ageing per se does not impair driving but in cases of medical conditions, such as cognitive impairment and dementia, driving safety can be impaired. Thus clinicians are often called upon to counsel patients and to make recommendations on their fitness to drive. Dementia in the early stages of the illness does not necessarily preclude driving ability. Patients with mild dementia pose a risk with respect to traffic safety and an individual assessment with regular follow-up investigations should be made. Especially patients with frontotemporal dementia should cease driving early in the course of the disease. Screening tests that focus on visuospatial abilities, attention and executive functions can improve the prediction of driving ability in patients with dementia. In many cases an on-road driving test to evaluate the ability to compensate for functional impairments is essential. In order to preserve personal autonomy as long as possible patients should be individually counselled taking into account driving experience, insight into functional impairments, personality and the capability to compensate for functional disabilities.

[Driving ability with affective disorders and under psychotropic drugs]. / Fahrtauglichkeit bei affektiven Störungen und unter Psychopharmaka.

There are only few data available regarding the effects of depressive disorders on road safety due to methodological shortcomings. Patients with acute severe depression or manias are unqualified for driving but after clinical remission driving ability can be attested under psychiatric supervision in most cases. So far there are only few data available about a patient's fitness to drive under psychotropic medication. Regarding the effects of antidepressants on road safety depressed patients obviously benefit from treatment with newer antidepressants; however, at least some subgroups of patients do not reach the performance level of healthy subjects. Approximately 17 % of remission bipolar patients must be regarded as unable to drive and 27 % of patients with schizophrenia on discharge from hospital. Benzodiazepines are clearly associated with increased risk of road traffic accidents. Impaired driving ability of young attention deficit hyperactivity disorder (ADHS) patients is improved under treatment with methylphenidate. Counselling patients with respect to driving ability must be carried out individually taking into account factors of the illness, personality, attitudes and coping strategies as well as different psychopharmacological effects.

[Principles of evaluating driving ability for neurological and psychiatric diseases]. / Grundlagen der Fahreignungsbeurteilung bei neurologischen und psychischen Erkrankungen.

If attending physicians and psychologists recognize restricted or a lack of driving ability they are obliged to inform their patients appropriately. In Germany the legal basis for assessing driving ability is the "Fahrerlaubnis-Verordnung" (FeV, driving licence act), supplemented by guidelines for evaluating driving ability. In each individual case it has to be clarified whether and to what extent permanent or paroxysmally occurring disorders affect driving ability and whether lack of insight ability or personality defects are a threat to driving safety. In addition, it has to be considered whether compensation opportunities exist that enable restricted driving ability. If an expert opinion is requested by the driving licence authority in Germany the medical expert must have a specific qualification and should not be the attending physician.

Driving ability under sertindole.

INTRODUCTION: Fitness to drive is an important prerequisite for the functional autonomy and thus also relevant for patients with a psychiatric illness. The efficacy of sertindole in the treatment of positive and negative schizophrenia symptoms has been shown in various studies. However, hitherto there exist no data about patients' fitness to drive under sertindole. METHODS: A non-randomized clinical study with 30 schizophrenic inpatients receiving sertindole (n=10), risperidone (n=10) or quetiapine (n=10) was conducted. Patients were tested under steady-state plasma level conditions prior to discharge to outpatient treatment. Data were collected with the computerized Act and React Testsystem (ART90) and the Wiener Determinationsgerät (WDG) measuring psychomotor skills relevant for fitness to drive. RESULTS: The main findings of this study are (i) that about 26% of schizophrenic patients, -following psychopathologic stabilization and prior discharge to outpatient treatment show severe impairments with respect to driving skills. (ii) Statistically significant differences between atypical antipsychotics could neither be demonstrated on the level of the global driving ability score nor on individual functional domains essential for fitness to drive. CONCLUSION: With respect to driving skills no differences have been found between patients treated with sertindole, risperidone or quetia-pine. However, a great proportion of schizophrenic patients partly remitted must be considered as unfit to drive, even when stabilized on treatment with atypical antipsychotics.

[Effects of psychoactive drugs on car driving ability]. / Fahrsicherheit und Psychopharmaka.

The mobility of many patients often depends on their using a motor vehicle. For this reason studies on their driving ability while under the influence of psychoactive drugs is of great practical relevance. These studies have shown that underlying factors of the illness itself represent a greater problem than drug-induced factors. When assessing pharmacologic effects on neuropsychological functions it has to be taken into account that patients' abilities take some time to stabilize after the acute phase of the disease. Driving ability while under the influence of psychoactive drugs must thus be judged over time. Marked interindividual variations in the reaction to psychoactive drugs always requires individual assessment of driving ability.

Cognitive deficits in schizophrenia and affective disorders: evidence for a final common pathway disorder.

This study was designed to determine whether patients with schizophrenia and those with affective disorders display a common pattern of cognitive deficits. Cognitive performance was assessed with a neuropsychological test battery in consecutively admitted in-patients with schizophrenia (n=100) and affective disorders (n=100). The two groups of patients showed a similar pattern of cognitive deficits, especially in tests focusing on attentional capacities. The groups only differed significantly in their performance on the Wisconsin Card Sorting Test (WCST), with the schizophrenic patients performing less well. These results suggest that, with the exception of the deficit as measured by the WCST, similar cognitive impairments exist in schizophrenia and affective disorders, even at very early stages of the illness. Therefore, patients with schizophrenia and those with affective disorders cannot be qualitatively distinguished with sufficient reliability. We postulate that the cognitive deficit pattern represents a final common pathway disorder in the two groups of patients.